US · RGC
Regencell Bioscience Holdings Limited
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Causeway Bay KY1-1107
- Website
- regencellbioscience.com
Price · as of 2025-06-30
$29.12
Market cap 12.97B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $0.69 | ||||
| 2022 | $0.89 | ||||
| 2023 | $0.39 | ||||
| 2024 | $0.18 | ||||
| 2025 | $13.26 |
AI valuation
Our deep-learning model estimates Regencell Bioscience Holdings Limited's (RGC) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $29.12
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| RGC | Regencell Bioscience Hold… | $29.12 | 12.97B | — | — | — | — | -1829.39 | 1349.09 | — | -2053.15 | — | 1349.09 | 0.00% | — | — | -54.81% | -886.14% | -50.50% | 0.11 | — | 7.39 | 7.38 | 0.59 | -1724.00% | — | -1849.00% | -0.05% | -4.69 | -767.74% | 0.00% | 0.00% | 0.00% | -1738.09 | -2006.13 | — | 4386.78 |
| ABVX | Abivax S.A. | $121.28 | 7.95B | -67% | -97% | — | — | -2.42 | 10.50 | 39.48 | -2.21 | — | 27.39 | 100.00% | -1602.89% | -1633.08% | -148.98% | 2618.19% | -66.22% | 2.40 | -41.33 | 1.84 | 1.72 | 0.27 | -1837.00% | 13354.00% | 5429.00% | -36.31% | -1.66 | 2341.68% | 0.00% | 0.00% | 0.00% | -2.19 | -2.45 | 35.14 | -3.71 |
| ATR | AptarGroup, Inc. | $143.71 | 9.43B | -31% | -59% | -82% | -45% | 23.88 | 3.52 | 2.48 | 12.63 | 366.80 | 7.03 | 29.58% | 13.53% | 10.40% | 15.28% | 11.48% | 8.11% | 0.57 | 9.69 | 1.62 | 1.04 | 1.36 | 651.00% | 542.00% | -1422.00% | 3.19% | 0.49 | 8.43% | 1.29% | 30.80% | 5.18% | 20.55 | 35.05 | 2.78 | 4.13 |
| AXSM | Axsome Therapeutics, Inc. | $163.89 | 8.38B | -38% | +8,512% | — | — | -45.19 | 93.74 | 12.96 | -48.76 | — | 231.63 | 92.56% | -26.51% | -28.69% | -252.11% | 574.69% | -29.11% | 2.73 | -25.81 | 1.55 | 1.44 | 0.49 | -3856.00% | 6555.00% | -2741.00% | -1.13% | -0.25 | 318.10% | 0.00% | 0.00% | 0.00% | -48.43 | -87.74 | 12.84 | 6.09 |
| CYTK | Cytokinetics, Incorporate… | $62.22 | 7.61B | -4% | -61% | — | — | -9.39 | -11.18 | 83.75 | -10.03 | -38.60 | -11.18 | 100.00% | -695.44% | -891.60% | 197.47% | 179.99% | -55.55% | -1.95 | — | 4.53 | 4.36 | -0.52 | 2433.00% | 37656.00% | 3377.00% | -7.25% | -2.52 | 157.23% | 0.00% | 0.00% | 3.96% | -12.70 | -14.54 | 88.31 | -2.06 |
| GRFS | Grifols, S.A. | $9.10 | 7.7B | +209% | -64% | — | -49% | 10.85 | 0.82 | 0.67 | 9.37 | 6.98 | -1.08 | 38.75% | 16.53% | 2.18% | 7.89% | 3.72% | 2.09% | 1.71 | 1.54 | 2.66 | 0.96 | 6.13 | 15556.00% | 941.00% | -67929.00% | 11.02% | 0.42 | 3.46% | 0.02% | 0.20% | 28.68% | 11.66 | 26.19 | 1.93 | 0.96 |
| MASI | Masimo Corporation | $175.35 | 9.42B | — | -60% | — | -71% | -62.06 | 13.04 | 6.16 | 31.37 | — | 16.55 | 61.90% | 20.30% | -9.92% | — | — | — | 0.72 | — | 2.49 | 1.40 | 1.17 | — | — | — | 2.10% | 0.58 | — | 0.00% | 0.00% | 3.87% | 31.51 | 49.38 | 6.40 | 8.77 |
| MRUS | Merus N.V. | $90.00 | 6.83B | -61% | -76% | — | -87% | -13.74 | 4.57 | 84.83 | -9.34 | -117.77 | 4.58 | 37.15% | -752.96% | -595.93% | -42.88% | -391.57% | -34.71% | 0.02 | — | 6.54 | 6.22 | 1.09 | 1167.00% | -1238.00% | 2826.00% | -6.34% | -2.13 | -279.56% | 0.00% | 0.00% | 3.06% | -9.26 | -12.97 | 69.71 | 11.12 |
| NUVL | Nuvalent, Inc. | $101.95 | 7.41B | — | — | — | — | -17.31 | 5.90 | — | -571.33 | -35.43 | 5.90 | 0.00% | — | — | -36.70% | 481.41% | -33.30% | 0.00 | — | 15.27 | 15.05 | 24.96 | 4885.00% | — | 4871.00% | -3.74% | -3.02 | 319.78% | 0.00% | 0.00% | 1.58% | -14.46 | -21.77 | — | 26.05 |
| RYTM | Rhythm Pharmaceuticals, I… | $92.73 | 6.19B | -37% | +215% | — | — | -31.39 | 44.36 | 32.51 | -33.22 | — | 46.13 | 89.73% | -101.19% | -106.41% | -129.46% | 96.50% | -45.05% | 0.03 | -9.33 | 4.41 | 3.92 | 0.29 | -2834.00% | 4583.00% | 241.00% | -1.89% | -1.09 | 58.61% | 0.09% | -2.70% | 0.09% | -30.13 | -49.60 | 30.48 | 13.65 |
| STVN | Stevanato Group S.p.A. | $15.52 | 4.24B | +118% | -45% | -52% | -68% | 31.27 | 3.57 | 4.54 | 21.56 | — | 3.80 | 27.38% | 14.60% | 10.67% | 12.64% | 7.41% | 7.29% | 0.31 | 23.48 | 1.84 | 1.32 | 1.33 | -2182.00% | 172.00% | -5314.00% | -3.15% | 0.33 | -9.88% | 0.29% | 9.00% | 0.29% | 33.16 | -33.86 | 4.84 | 4.68 |
About Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
- CEO
- Yat-Gai Au
- Employees
- 12
- Beta
- 2.01
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $29.12) − 1 = — (DCF, example).